CA2486490A1 - Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation - Google Patents

Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation Download PDF

Info

Publication number
CA2486490A1
CA2486490A1 CA002486490A CA2486490A CA2486490A1 CA 2486490 A1 CA2486490 A1 CA 2486490A1 CA 002486490 A CA002486490 A CA 002486490A CA 2486490 A CA2486490 A CA 2486490A CA 2486490 A1 CA2486490 A1 CA 2486490A1
Authority
CA
Canada
Prior art keywords
nucleic acid
polypeptide
novx
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002486490A
Other languages
English (en)
Inventor
David W. Anderson
Ferenc L. Boldog
Catherine E. Burgess
Stacie J. Casman
Shlomit R. Edinger
Andrew Eisen
Karen Ellerman
Valerie L. Gerlach
Linda Gorman
Xiaojia Guo
Vladimir Y. Gusev
Weizhen Ji
Li Li
John R. Macdougall
Uriel M. Malyankar
Isabelle Millet
Tatiana Ort
Muralidhara Padigaru
Sudhirdas K. Prayaga
Meera Patturajan
Carol E. A. Pena
John A. Peyman
Daniel K. Rieger
Mark E. Rothenberg
Paul Sciore
Suresh G. Shenoy
Glennda Smithson
Kimberly A. Spytek
David J. Stone
Raymond J. Taupier, Jr.
Velizar T. Tchernev
Corine A. M. Vernet
Edward Z. Voss
Bryan D. Zerhusen
Mei Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/454,246 external-priority patent/US20050053930A1/en
Application filed by CuraGen Corp filed Critical CuraGen Corp
Publication of CA2486490A1 publication Critical patent/CA2486490A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des séquences d'acides nucléiques qui codent de nouveaux polypeptides. L'invention concerne également des polypeptides codés par ces séquences d'acides nucléiques et des anticorps qui se lient par immunospécificité à ces polypeptides, ainsi que des dérivés, des variantes, des mutants ou des fragments des nouveaux polypeptides, polynucléotides ou anticorps spécifiques des polypeptides. L'invention concerne enfin des procédés thérapeutiques, de diagnostic et de recherche destinés au diagnostic, au traitement et à la prévention de troubles dans lesquels sont impliqués l'un ou l'autre des protéines et acides nucléiques humains de l'invention.
CA002486490A 2002-03-19 2003-06-04 Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation Abandoned CA2486490A1 (fr)

Applications Claiming Priority (43)

Application Number Priority Date Filing Date Title
US36549102P 2002-03-19 2002-03-19
US60/365,491 2002-03-19
US38550402P 2002-06-04 2002-06-04
US60/385,504 2002-06-04
US38604102P 2002-06-05 2002-06-05
US60/386,041 2002-06-05
US38697402P 2002-06-06 2002-06-06
US38645302P 2002-06-06 2002-06-06
US60/386,974 2002-06-06
US60/386,453 2002-06-06
US38681602P 2002-06-07 2002-06-07
US38700202P 2002-06-07 2002-06-07
US60/386,816 2002-06-07
US60/387,002 2002-06-07
US38754002P 2002-06-10 2002-06-10
US60/387,540 2002-06-10
US38765902P 2002-06-11 2002-06-11
US60/387,659 2002-06-11
US38793402P 2002-06-12 2002-06-12
US60/387,934 2002-06-12
US38912302P 2002-06-13 2002-06-13
US60/389,123 2002-06-13
US38972902P 2002-06-17 2002-06-17
US38974202P 2002-06-17 2002-06-17
US60/389,742 2002-06-17
US60/389,729 2002-06-17
US39000602P 2002-06-19 2002-06-19
US60/390,006 2002-06-19
US39670602P 2002-07-17 2002-07-17
US60/396,706 2002-07-17
US40283202P 2002-08-12 2002-08-12
US60/402,832 2002-08-12
US40348602P 2002-08-13 2002-08-13
US60/403,486 2002-08-13
US40352202P 2002-08-14 2002-08-14
US60/403,522 2002-08-14
US40374802P 2002-08-15 2002-08-15
US60/403,748 2002-08-15
US38703702P 2002-11-06 2002-11-06
US60/387,037 2002-11-06
US10/454,246 2003-06-03
US10/454,246 US20050053930A1 (en) 2000-07-18 2003-06-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PCT/US2003/017512 WO2004000997A2 (fr) 2002-03-19 2003-06-04 Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation

Publications (1)

Publication Number Publication Date
CA2486490A1 true CA2486490A1 (fr) 2003-12-31

Family

ID=34140035

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002486490A Abandoned CA2486490A1 (fr) 2002-03-19 2003-06-04 Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation

Country Status (2)

Country Link
CA (1) CA2486490A1 (fr)
WO (1) WO2004000997A2 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
EP1907580A2 (fr) * 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Procede pour le diagnostic et le traitement d'hypernephrome
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2016394A4 (fr) 2006-04-04 2013-04-24 Singulex Inc Procédés et compositions d'analyse extrêmement sensible de marqueurs et de détection de molécules
EP2440936A4 (fr) 2009-06-08 2013-03-13 Singulex Inc Groupes de biomarqueurs très sensibles
EP2448966B1 (fr) 2009-07-03 2018-11-14 Avipep Pty Ltd Immunoconjugués et leurs procédés de production
IN2012DN03025A (fr) 2009-09-09 2015-07-31 Ct Se Llc
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
US20130028917A1 (en) 2010-04-15 2013-01-31 Spirogen Developments Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2011156328A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
EP2640727B1 (fr) 2010-11-17 2015-05-13 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
CA2833404A1 (fr) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Molecules a domaine variable modifie et procedes de preparation et d'utilisation de celles-ci
JP5987053B2 (ja) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
AU2012322607B2 (en) 2011-10-14 2017-02-16 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
LT2906253T (lt) 2012-10-12 2018-10-10 Adc Therapeutics Sa Pirolobenzodiazepino-anti-psma antikūno konjugatas
EP2906297B1 (fr) 2012-10-12 2017-12-06 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
EP2906298B1 (fr) 2012-10-12 2018-10-03 ADC Therapeutics SA Conjugués pyrrolobenzodiazépine-anticorps
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
ME03486B (fr) 2012-10-12 2020-01-20 Medimmune Ltd Pyrrolobenzodiazépines et ses conjugués
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
CA2887899C (fr) 2012-10-12 2020-03-31 Adc Therapeutics Sarl Conjugues anticorps anti-cd22 - pyrrolobenzodiazepine
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
AR096287A1 (es) 2013-03-13 2015-12-23 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados
CA2904044C (fr) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines et leurs conjugues
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
WO2015052532A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépines
MX2016007578A (es) 2013-12-16 2016-10-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
MX2016007826A (es) 2013-12-16 2017-03-31 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CA2968447A1 (fr) 2014-11-25 2016-06-02 Adc Therapeutics Sa Conjugues anticorps-pyrrolobenzodiazepine
CA2969689A1 (fr) 2014-12-03 2016-06-09 Genentech, Inc. Composes d'amine quaternaire et conjugues anticorps-medicament de ceux-ci
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3433621A1 (fr) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
EP3464280B1 (fr) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20200032243A (ko) 2017-02-08 2020-03-25 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
EP3612234B1 (fr) 2017-04-20 2024-03-13 ADC Therapeutics SA Polythérapie avec un conjugué anticorps anti-axl-médicament
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
DK3668874T3 (da) 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepin-konjugater
RU2020113749A (ru) 2017-09-20 2021-10-20 пиЭйч ФАРМА Ко., ЛТД. Аналоги таиланстатина
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (zh) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 綴合化學降解誘導劑及使用方法
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use

Also Published As

Publication number Publication date
WO2004000997A2 (fr) 2003-12-31
WO2004000997A3 (fr) 2007-08-16

Similar Documents

Publication Publication Date Title
CA2486490A1 (fr) Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation
CA2451454A1 (fr) Polypeptides therapeutiques, acides nucleiques les codant, et modalites d'emploi correspondantes
US20030199442A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2455389A1 (fr) Polypeptides therapeutiques, acides nucleiques codant ceux-ci et procedes d'utilisation
CA2451254A1 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
CA2460653A1 (fr) Polypeptides therapeutiques, acides nucleiques les codant et procedes d'utilisation correspondant
CA2455225A1 (fr) Nouvelle proteines et acides nucleiques codant celles-ci
US20030224982A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2480450A1 (fr) Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees
CA2463325A1 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
US20040067505A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2470012A1 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
CA2442739A1 (fr) Nouveaux anticorps se liant a des polypeptides antigeniques, acides nucleiques codant pour ces antigenes, et procedes d'utilisation de ceux-ci
CA2471480A1 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et procedes d'utilisation
WO2004089282A2 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides, et procedes d'utilisation correspondants
US20040229779A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040058338A1 (en) Novel proteins and nucleic acids encoding same
CA2485089A1 (fr) Polypeptides therapeutiques, acides nucleiques codant pour lesdits polypeptides et methodes d'utilisation
CA2467721A1 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et methodes d'utilisation
CA2446427A1 (fr) Polypeptides therapeutiques, acides nucleiques les codant et methodes d'utilisation
CA2481039A1 (fr) Polypeptides therapeutiques, acides nucleiques les codant et leurs procedes d'utilisation
US20040002453A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20050037957A1 (en) Novel proteins and nucleic acids encoding same
CA2440345A1 (fr) Nouveaux anticorps se liant a des polypeptides antigeniques, acides nucleiques codant pour les antigenes et procedes d'utilisation
US20030087274A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Legal Events

Date Code Title Description
FZDE Discontinued